Drug companies making these medicines were forced to revise prices after the Centre capped trade margins on these drugs at 30 per cent, under the Supreme Court’s watch
The revised prices on 137 anti-cancer drugs will kick in on Monday, bringing annual savings of over ₹3,500 crore, said a note from the National Pharmaceutical Pricing Authority (NPPA).
Drug companies making these medicines were forced to revise prices after the Centre capped trade margins on these drugs at 30 per cent, under the Supreme Court’s watch.
Giving the latest update, the NPPA said on Saturday, about 76 pharmaceutical companies have revised MRPs for 1225 anti-cancer formulations, covering 121 drugs. A reduction has been reported in 1031 formulations of anti-cancer medicines, with 600 brands reporting above 50 per cent reduction, and the highest reduction being 96.45 per cent, the NPPA said.
In fact, it said, about 10-15 drugs (of the 137) were yet to be launched in India, and the Trade Margin Rationalisation (TMR) will be applicable to them when they are brought into the country. According to a source, of 1330 updated prices, about 203 brand prices remain unchanged.
“Every retailer, dealer, hospital and institution is required to prominently display the revised MRP list of anti-cancer medicines on their websites and in their premises,” the NPPA said.
Some of the medicines seeing a reduction in prices included:
# Bevacizumab 100 MG Injection (for Lung, Colon, Ovary and Cervical Cancer) – with Zydus Lifesciences price reducing from ₹ 25,995 to ₹3,318;
# Denosumab 60 MG Injection (for breast and prostate cancer – prevents bone loss) – Reliance Life Sciences – down from ₹ 24,955 to ₹6,240;
# Abiraterone acetate 250 MG Tablet (for Prostate Cancer) – Arvincare Pharma – ₹41,250 to ₹3,218.23;
# Pegfilgrastim 6 MG Injection (to prevent neutropenia in cancer patients) – Reliance Life Sciences Private Limited – ₹7,790.00 to ₹ 1,397.00
# Enzalutamide 40 MG Capsule (for prostate cancer) – Halsted Pharma – from ₹20,625.00 to ₹2,475.60
# Fulvestrant 250 mg Injection (for breast cancer) – Eris Lifesciences – ₹30,421.87 to ₹3,671.73
# Palbociclib 125 MG Capsule (for breast cancer) – RPG Lifesciences – ₹40,421.33 to ₹2,720.00
# Pemetrexed 500 MG Vial (for lung cancer) – Reliance Life Sciences Private Limited – ₹9,977.00 to ₹1,113.00
# Pertuzumab 420 MG Injection (for breast cancer) – Lupin Limited – ₹83,520.00 – ₹37,358.35
Published on November 7, 2026
